Coronavirus Treatment Drugs Market Growth Accelerated By R&D Investments In New Drug Discovery
![]() |
Coronavirus Treatment Drugs Market |
Coronavirus treatment drugs are used for the treatment of
various strains of coronavirus including COVID-19, SARS, MERS and others. These
drugs help prevent and treat the symptoms of coronaviruses. The growing
prevalence of coronaviruses and urgent need to develop effective treatment
options is driving research and development activities in this market. The
global Coronavirus Treatment Drugs Market is estimated to be valued at US$ 25812.99
Mn in 2023 and is expected to exhibit a CAGR
of 3.5% over the forecast period 2024 to 2031, as highlighted in a new
report published by Coherent Market Insights.
Market key trends:
R&D investments in new drug discovery to treat coronavirus infections
has been one of the key trends observed in the coronavirus treatment drugs
market. Following the COVID-19 outbreak, pharmaceutical companies and research
institutes have increased focus on the development of therapeutics and
vaccines. For instance, Gilead Sciences' remdesivir was the first drug to
receive FDA approval for treatment of hospitalized COVID-19 patients. The
company has invested over US$ 1 Bn in R&D for remdesivir. Similarly, other
leading players such as Pfizer, Merck, Johnson & Johnson and AstraZeneca
have allocated large R&D budgets for clinical trials and research on
coronavirus treatment drugs. This heavy investment in new drug development is
expected to drive the coronavirus treatment drugs market growth over the
forecast period.
Segment Analysis
The global
coronavirus treatment drugs market is segmented into antiviral drugs, immune
support drugs, monoclonal antibodies and vaccines. Among these, antiviral drugs
dominate the market with over 37% share. This is because antiviral drugs
directly target the virus and inhibit its replication mechanism. Some of the
commonly used antiviral drugs to treat coronavirus include remdesivir,
favipiravir and lopinavir/ritonavir.
Key Takeaways
The global
coronavirus treatment drugs market demand is expected to witness high
growth in the coming years.
Regional analysis shows that North America currently
dominates the market with over 41% share owing to large spend on healthcare and
biomedical research in the US. However, Asia Pacific is estimated to grow at
the fastest pace during the forecast period of 2023-2030 as the epidemic
spreads across emerging countries in this region including India and China.
Key players
operating in the coronavirus treatment drugs market are F.
Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Regeneron Pharmaceuticals Inc.,
and Shionogi & Co., Ltd. F. Hoffmann-La Roche Ltd leads the market with its
antiviral drug remdesivir (Veklury) which was the first treatment approved by
the US FDA for coronavirus.
Get more insights on this topic: https://www.newswirestats.com/coronavirus-treatment-drugs-market-industry-insights-trends-coronavirus-treatment-drugs-market/
Comments
Post a Comment